INmune Bio Inc reports results for the quarter ended in September - Earnings Summary

Inmune Bio

02/11/2023 07:30

* INmune Bio Inc  INMB.OQ  reported a quarterly adjusted
loss
of 48 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -43 cents.  The mean expectation of three analysts for
the quarter was for a loss of 39 cents per share. Wall Street
expected results to range from -40 cents to -39 cents per share.
    * Revenue fell 56.1% to $43.00 thousand from a year ago;
analysts
expected zero. 
    * INmune Bio Inc's reported EPS for the quarter was a loss
of 48
cents​.
    * The company reported a quarterly loss of $8.56 million.
    * INmune Bio Inc shares had risen by 4.4% this quarter and
gained 11.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for INmune Bio Inc is
$16.00 
This summary was machine generated from LSEG data November 2 at
07:30 a.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.39          -0.48          Missed
 Jun. 30 2023      -0.40          -0.36          Beat
 Mar. 31 2023      -0.02          -0.36          Missed
 Dec. 31 2022      -0.48          -0.32          Beat